Particle.news
Download on the App Store
6 ARTICLES
·
last wk.

White House Secures 9 More Pharma Deals, Bringing Total to 14 to Curb U.S. Drug Prices

Companies secured three-year tariff exemptions in return for MFN pricing commitments.

Donald Trump departs after delivering remarks on lowering prescription drug prices at an event in the Roosevelt Room of the White House on December 19, 2025, in Washington, D.C.
Image
Pharmacist recommends medicines to customers. Asking the questions of medication. Professional Asian male pharmacist giving prescription medications to female patient customers at drugstore shelves.
Image

Overview

  • Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi signed on, joining five firms that reached earlier agreements.
  • The agreements commit MFN-style pricing for many Medicaid drugs, launch-price parity with other wealthy countries, and cash-pay discounts to be routed through TrumpRx.gov starting in early 2026.
  • The White House cited examples for the direct-purchase portal, including Amgen’s Repatha at $239 a month and Merck’s Januvia at $100, with additional drugs listed by participating companies.
  • In exchange, drugmakers receive three-year exemptions from potential tariffs and have collectively pledged more than $150 billion for U.S. manufacturing and R&D, with contributions to an emergency API reserve.
  • Advocates and some lawmakers questioned the opaque, voluntary deals and the real-world savings for insured patients and Medicaid enrollees, while AbbVie, Johnson & Johnson and Regeneron remain unsigned with further announcements suggested by the administration.